Biotech News
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe
Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. 1,2,3
Biotech News
Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. 1,2,3
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.